A Biomarker‐Based Classification of Corticobasal Syndrome
Movement Disorders · 2026-01 · 41 (1) · 129-142
DOI: 10.1002/mds.70070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 06.10.2025. Verfasst von Carla Palleis und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany. Hauptthemen laut MEDLINE: Corticobasal Degeneration. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Alzheimer Forschung Initiative, German Center for Neurodegenerative Diseases.
Abstract (Originalsprache)
Background
Corticobasal syndrome (CBS) is a clinically defined syndrome with progressive movement and cortical dysfunction, caused by various underlying pathologies, most commonly tau‐predominant pathologies such as progressive supranuclear palsy and corticobasal degeneration, or Alzheimer's disease (AD). Lewy‐type α‐synucleinopathies (LTS), TDP‐43 proteinopathies, and mixed pathologies may also underlie CBS. The clinical impact of these pathologies remains poorly understood.
Objectives
To subclassify CBS patients in vivo using biomarkers for amyloid‐β (Aβ), Tau, and α‐synuclein (αSyn), and assess the clinical relevance of this stratification.
Methods
We conducted a prospective cohort study of 50 CBS patients at LMU University Hospital Munich. Biomarker analysis included cerebrospinal fluid (CSF) Aβ42 and Aβ42/40, [ 18 F]flutemetamol Aβ‐PET, [ 18 F]PI‐2620 tau‐PET, and αSyn seed amplification assays in CSF. CSF neurofilament light chain (NfL) served as a marker of neurodegeneration. Patients were stratified into six groups based on biomarker positivity.
Results
Tau positivity was found in 90% of CBS cases, Aβ in 28%, and αSyn in 24%. Stratification identified: 52% consistent with tau‐predominant pathology, 18% with AD, 10% with AD+LTS, 10% with tau‐predominant+LTS, 4% with isolated LTS, and 6% unclassified. αSyn positivity was more frequent in AD‐CBS (36%) than in tau‐predominant‐CBS (16%). Aβ‐positive cases showed greater cognitive impairment; Tau positivity correlated with worse motor symptoms; αSyn‐positive patients had milder motor symptoms, slower progression, and lower NfL levels.
Conclusions
CBS is molecularly heterogeneous. Biomarker‐based classification may enhance diagnostic precision and support personalized therapeutic strategies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
- German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
- Schön Klinik München Schwabing, Munich, Germany.
- Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
- Institute for Stroke and Dementia Research (ISD), LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
ORCID-Profile: Carla Palleis, Alexander Maximilian Bernhardt, Sabrina Katzdobler, Matthias Brendel
Förderung
- Deutsche Forschungsgemeinschaft
- Alzheimer Forschung Initiative
- German Center for Neurodegenerative Diseases
- German Parkinson's Association
- Alzheimer Forschung Initiative e.V.
- Munich Cluster for Systems Neurology
- German Ministry of Research and Education
- NOMIS Foundation
Zitieren
APA
Palleis, C., Bernhardt, A. M., Weidinger, E., Fietzek, U. M., Jäck, A., Katzdobler, S., Gnörich, J., Bauer, T., Franzmeier, N., Perneczky, R., German Imaging Initiative for Tauopathies (GII4T), Brendel, M., Levin, J., & Höglinger, G. U. (2026). A Biomarker‐Based Classification of Corticobasal Syndrome. Movement Disorders, 41(1), 129-142. https://doi.org/10.1002/mds.70070
Vancouver
Palleis C, Bernhardt AM, Weidinger E, Fietzek UM, Jäck A, Katzdobler S, et al. A Biomarker‐Based Classification of Corticobasal Syndrome. Movement Disorders. 2026;41(1):129-142. doi:10.1002/mds.70070
BibTeX
@article{Palleis2026,
author = {Palleis, Carla and Bernhardt, Alexander Maximilian and Weidinger, Endy and Fietzek, Urban M and Jäck, Alexander and Katzdobler, Sabrina and Gnörich, Johannes and Bauer, Theresa and Franzmeier, Nicolai and Perneczky, Robert and German Imaging Initiative for Tauopathies (GII4T), German Imaging Initiative for Tauopathies (GII4T) and Brendel, Matthias and Levin, Johannes and Höglinger, Günter U},
title = {A Biomarker‐Based Classification of Corticobasal Syndrome},
journal = {Movement Disorders},
year = {2026},
volume = {41},
number = {1},
pages = {129--142},
doi = {10.1002/mds.70070}
}
EUVIMED